Accueil   Diary - News   All news EVOTEC BIOLOGICS to produce monoclonal antibody products against Covid-19 for the Department of Defense

EVOTEC BIOLOGICS to produce monoclonal antibody products against Covid-19 for the Department of Defense

 

Hamburg, Germany, 22 July 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and manufacture monoclonal antibodies (“mAbs”) for treatment and/or prevention of COVID-19. The goal of this programme is to rapidly and efficiently deliver the mAbs to the DOD.

 

Read the press release